drugset / Trial / NCT00639743

PEITHO Pulmonary Embolism Thrombolysis Study

NCT00639743

RandomizedParallel-groupDouble-blindTreatment

Summary

Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients included in those studies is too low. The aim of the study is to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary embolism) in a large group of patients with sub-massive pulmonary embolism.

Timeline

Start
2007-11-16
Primary completion
2012-07-26
Completion
2014-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 30 mg Intravenous
Subject Tenecteplase Protein / enzyme biologic 35 mg Intravenous
Subject Tenecteplase Protein / enzyme biologic 40 mg Intravenous
Subject Tenecteplase Protein / enzyme biologic 45 mg Intravenous
Subject Tenecteplase Protein / enzyme biologic 50 mg Intravenous

Indications